Literature DB >> 26995353

Hollow-Fiber Methodology for Pharmacokinetic/Pharmacodynamic Studies of Antimalarial Compounds.

Emily Caton1, Elizabeth Nenortas1, Rahul P Bakshi1, Theresa A Shapiro1.   

Abstract

Knowledge of pharmacokinetic/pharmacodynamic (PK/PD) relationships can enhance the speed and economy of drug development by enabling informed and rational decisions at every step, from lead selection to clinical dosing. For anti-infective agents in particular, dynamic in vitro hollow-fiber cartridge experiments permit exquisite control of kinetic parameters and the study of their consequent impact on pharmacodynamic efficacy. Such information is of great interest for the cost-restricted but much-needed development of new antimalarial drugs, especially since the major human pathogen Plasmodium falciparum can be cultivated in vitro but is not readily available in animal models. This protocol describes the materials and procedures for determining the PK/PD relationships of antimalarial compounds.
Copyright © 2016 John Wiley & Sons, Inc.

Entities:  

Keywords:  Plasmodium falciparum; drug development; dynamic PK/PD; hollow-fiber cartridge system; malaria; pharmacodynamics; pharmacokinetics

Mesh:

Substances:

Year:  2016        PMID: 26995353      PMCID: PMC4811375          DOI: 10.1002/9780470559277.ch150194

Source DB:  PubMed          Journal:  Curr Protoc Chem Biol        ISSN: 2160-4762


  17 in total

Review 1.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

Authors:  George L Drusano
Journal:  Nat Rev Microbiol       Date:  2004-04       Impact factor: 60.633

2.  Two compartment kinetic model with multiple artificial capillary units.

Authors:  J Blaser; B B Stone; S H Zinner
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

3.  Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system.

Authors:  Ashley N Brown; James J McSharry; Qingmei Weng; Jonathan R Adams; Robert Kulawy; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

4.  Determination of the cytostatic and cytocidal activities of antimalarial compounds and their combination interactions.

Authors:  Katy S Sherlach; Paul D Roepe
Journal:  Curr Protoc Chem Biol       Date:  2014-12-01

5.  Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique.

Authors:  R E Desjardins; C J Canfield; J D Haynes; J D Chulay
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

6.  Model system to define pharmacokinetic requirements for antimalarial drug efficacy.

Authors:  Rahul P Bakshi; Elizabeth Nenortas; Abhai K Tripathi; David J Sullivan; Theresa A Shapiro
Journal:  Sci Transl Med       Date:  2013-10-02       Impact factor: 17.956

7.  The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.

Authors:  Michael Delves; David Plouffe; Christian Scheurer; Stephan Meister; Sergio Wittlin; Elizabeth A Winzeler; Robert E Sinden; Didier Leroy
Journal:  PLoS Med       Date:  2012-02-21       Impact factor: 11.069

Review 8.  The global pipeline of new medicines for the control and elimination of malaria.

Authors:  Melinda P Anthony; Jeremy N Burrows; Stephan Duparc; Joerg J Moehrle; Timothy N C Wells
Journal:  Malar J       Date:  2012-09-07       Impact factor: 2.979

9.  Fast in vitro methods to determine the speed of action and the stage-specificity of anti-malarials in Plasmodium falciparum.

Authors:  Claire Le Manach; Christian Scheurer; Sibylle Sax; Sarah Schleiferböck; Diego Gonzalez Cabrera; Yassir Younis; Tanya Paquet; Leslie Street; Peter Smith; Xavier C Ding; David Waterson; Michael J Witty; Didier Leroy; Kelly Chibale; Sergio Wittlin
Journal:  Malar J       Date:  2013-11-16       Impact factor: 2.979

10.  Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis.

Authors:  George L Drusano; Michael Neely; Michael Van Guilder; Alan Schumitzky; David Brown; Steven Fikes; Charles Peloquin; Arnold Louie
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

View more
  3 in total

1.  Kinetic Driver of Antibacterial Drugs against Plasmodium falciparum and Implications for Clinical Dosing.

Authors:  Emily Caton; Elizabeth Nenortas; Rahul P Bakshi; Theresa A Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

2.  A microfluidic system that replicates pharmacokinetic (PK) profiles in vitro improves prediction of in vivo efficacy in preclinical models.

Authors:  Dharaminder Singh; Sudhir P Deosarkar; Elaine Cadogan; Vikki Flemington; Alysha Bray; Jingwen Zhang; Ronald S Reiserer; David K Schaffer; Gregory B Gerken; Clayton M Britt; Erik M Werner; Francis D Gibbons; Tomasz Kostrzewski; Christopher E Chambers; Emma J Davies; Antonio Ramos Montoya; Jacqueline H L Fok; David Hughes; Kristin Fabre; Matthew P Wagoner; John P Wikswo; Clay W Scott
Journal:  PLoS Biol       Date:  2022-05-26       Impact factor: 9.593

3.  Model System Identifies Kinetic Driver of Hsp90 Inhibitor Activity against African Trypanosomes and Plasmodium falciparum.

Authors:  Kirsten J Meyer; Emily Caton; Theresa A Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.